The FDA has approved fam-trastuzumab deruxtecan-nxki for neoadjuvant or adjuvant treatment of HER2-positive early-stage breast cancer. The U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for two indications in adult patients...
The FDA has approved atezolizumab or atezolizumab and hyaluronidase-tqjs as adjuvant therapy for muscle-invasive bladder cancer. The U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as adjuvant...
Relacorilant was approved for previously treated ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved relacorilant (Lifyorli) in combination with nab-paclitaxel for the treatment of platinum-resistant epithelial ovarian,...
The FDA has approved teclistamab with daratumumab hyaluronidase-fihj for certain patients with pretreated multiple myeloma. The U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj (Darzalex Faspro) for adult...
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment of certain colorectal cancers. The U.S. Food and Drug Administration (FDA) has granted traditional approval...
The FDA has approved the portable device Optune Pax for non-invasive at-home treatment of locally advanced pancreatic cancer. The U.S. Food and Drug Administration (FDA) approved Optune Pax, a portable, noninvasive device for the...
The FDA has approved daratumumab and hyaluronidase-fihj in combination with other therapies as first-line treatment for certain patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro)...
Patients now have the option of receiving the bispecific antibody amivantamab as an injection. The U.S. Food and Drug Administration (FDA) has approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for subcutaneous injection as an alternative...
The FDA has converted the accelerated approval of rucaparib to full approval for certain patients with metastatic castration-resistant prostate cancer. The U.S. Food and Drug Administration (FDA) has granted traditional approval to rucaparib (Rubraca)...
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More